The Drug Enforcement Administration (DEA) today issued new guidance addressing when a DEA-registered pharmacy may deliver a patient-specific controlled substance directly to a practitioner for administration to that patient. 21 USC 829a.
The guidance, titled Delivery of a Prescribed Controlled Substance by a Drug Enforcement Administration (DEA)-Registered Pharmacy to a Practitioner for Direct Administration to the Patient under Power of Attorney (POA), establishes a pathway in which a patient may execute a power of attorney (POA), consistent with state law, authorizing an administering practitioner to accept delivery of the patient’s prescribed controlled substance on the patient’s behalf.
Why Did DEA Issue This Guidance concerning 21 USC 829a?
Under the Controlled Substances Act (CSA), a pharmacy generally dispenses a controlled substance directly to the ultimate user, meaning the patient or a member of the patient’s household. A practitioner generally cannot simply receive a patient’s dispensed controlled substance from a pharmacy because the practitioner is not the ultimate user. The CSA has only limited exceptions to this general rule, as set forth in 21 USC 829a.
DEA acknowledges, however, that certain controlled substances either must be delivered directly to a practitioner because of FDA requirements or should be delivered directly to a practitioner for quality-control or other reasons. DEA specifically identifies medications intended for delivery through intrathecal pumps as an example and notes the importance of sterility with these medications.
The new guidance provides an additional option for addressing this situation – an option not found in the CSA itself.
The New 21 USC 829a POA Pathway
Under DEA’s guidance, a patient with a qualifying controlled-substance prescription may execute a POA, consistent with applicable state law, designating the administering practitioner as the patient’s agent for the limited purpose of accepting delivery of the patient’s prescribed medication from the dispensing pharmacy.
This aspect of the new guidance – whereby the practitioner is considered the agent of the patient – bears emphasis.
As stated in the guidance, the practitioner receives the medication as the patient’s agent, not in the practitioner’s capacity as a DEA registrant. The practitioner cannot take actions with the medication that the patient could not legally take and cannot take actions beyond those specifically authorized by the POA.
DEA also states that this pathway is limited to controlled substances that must under FDA requirements, or should for quality-control or other reasons, be delivered directly to an administering practitioner for administration in a healthcare setting.
This Is Not Office Stock
One of the most important compliance distinctions in the guidance is the difference between a patient-specific dispensed prescription (which the guidance applies to) and controlled substances maintained as a practitioner’s office stock (which the guidance does not apply to).
When utilizing the 21 USC 829a POA pathway under the guidance, DEA indicates that the following conditions should exist:
- The prescription should be for a dose intended for direct administration to a specifically named patient.
- It should not be a take-home supply for the patient.
- It should not be used as office stock.
- The medication may be administered only to the patient named on the prescription.
- The administering practitioner must keep the dispensed medication separate from controlled substances maintained under the practitioner’s DEA registration.
In light of DEA specifying these conditions, a sound practice for an organization who chooses to utilize the new guidance would be to memorialize this process in their policies and procedures.
Pharmacy Responsibilities
The guidance also establishes several important considerations for the dispensing pharmacy.
The pharmacy must continue to comply with the applicable CSA and DEA dispensing requirements. DEA states that records should document that the controlled substance was delivered to the practitioner and should identify the practitioner’s name and the address where the medication was delivered.
Another condition specified in the new guidance is that the medication be delivered to the prescribing or administering practitioner, as applicable, at the address specified in the POA.
DEA also recommends that pharmacies take steps to verify the existence and validity of the POA before dispensing. Importantly, the existence of a POA does not eliminate the pharmacy’s responsibility to determine that it is dispensing pursuant to a valid prescription. DEA specifically warns that inadequate verification of a POA may create diversion risk and potentially expose the pharmacy to violations of state or federal law.
DEA further recommends that pharmacies consider maintaining a copy of the 21 USC 829a POA for at least two years after the last delivery or administration under the POA, or longer when required by applicable law.
Practitioner Responsibilities
The POA does not eliminate a practitioner’s existing controlled-substance obligations.
DEA reiterates that prescriptions must be issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice, consistent with 21 CFR 1306.04(a), and must contain the information required by applicable DEA regulations.
Practitioners also remain responsible for maintaining effective controls and procedures against theft and diversion under 21 CFR 1301.71(a).
DEA recommends that the administering practitioner consider retaining the POA for at least two years after the last delivery or administration, or longer where required by law.
What Happens to Unused or Waste Medication?
The guidance raises another particularly important operational issue.
Once the controlled substance has been dispensed to the patient, DEA considers it to have left the CSA’s closed system of distribution. Under the 21 USC 829a POA arrangement, the practitioner is receiving that medication as the patient’s agent, rather than receiving inventory as a DEA registrant.
If that dispensed controlled substance subsequently becomes unwanted or waste, DEA states that it cannot be returned to a DEA registrant. Instead, it must be disposed of by the ultimate user through an authorized mail-back package or collection receptacle consistent with the regulations cited in the guidance.
For healthcare organizations considering this pathway, that distinction deserves particular attention when developing procedures for unused medications.
DEA’s Choice of the Word “Agent” in this Context
As indicated above, in this new guidance document, DEA states that the POA makes the practitioner the “agent” of the patient. On a different topic, in a document DEA published in 2010 titled “Role of Authorized Agents in Communicating Controlled Substance Prescriptions to Pharmacies” (which described, for CSA purposes, when a valid agency relationship exists between a prescribing practitioner and another person for the purpose of communicating a prescription for a controlled substance to a pharmacy), DEA stated that it was appropriate to rely on the Restatement of Agency in deciding whether an actual agency relationship exists. Under that Restatement definition, one of the requirements of having an agency relationship is that the agent is subject to the control of the principal. DEA does not address that prior DEA publication in the new guidance document or otherwise expand on the meaning of “agent” in the new guidance document.
Existing Exceptions Are Not Changed
It should also be noted that the guidance states it does not change the separately authorized delivery mechanisms under 21 USC 829a for certain Schedule III-V controlled substances.
DEA identifies two existing categories, which are set forth in 21 USC 829a and remain in effect:
- Schedule III-V controlled substances administered by injection or implantation for maintenance or detoxification treatment; and
- Certain Schedule III-V medications subject to an FDA Risk Evaluation and Mitigation Strategy (REMS) requiring specified patient monitoring, including applicable post-administration monitoring.
What Should Pharmacies and Practitioners Consider?
Organizations considering use of this pathway should pay particular attention to several areas:
- Whether the medication actually falls within the circumstances described by DEA;
- Whether the proposed POA complies with applicable state law;
- Procedures for verifying the POA before a pharmacy releases the medication;
- Documentation of the practitioner and delivery location;
- Physical separation of patient-specific medication from the practitioner’s DEA-registered controlled-substance inventory;
- Controls against theft and diversion;
- Procedures addressing unused or unwanted medication; and
- Appropriate retention of POA documentation.
DEA says in the guidance that it does not prescribe a particular form or structure for the 21 USC 829a POA beyond requiring consistency with state law, and its two-year retention recommendation is presented as a consideration rather than as a new mandatory federal POA retention requirement. 21 USC 829a.
The Bottom Line
DEA’s October 2026 guidance provides a potentially useful pathway for circumstances where patient-specific controlled substances need to move directly from a pharmacy to the practitioner who will administer them.
According to DEA, the POA does not transform the medication into practitioner inventory. The practitioner accepts the medication as the patient’s agent, the medication remains patient-specific, and the existing responsibilities surrounding valid prescribing, dispensing, security, diversion prevention, and state-law compliance remain in place.
DEA also emphasizes that this pathway is optional. It is neither the preferred nor exclusive method, and neither patients nor DEA registrants are required to establish a POA program. The guidance itself is non-binding and does not have the force and effect of law.
For pharmacies, hospitals, physician practices, infusion providers, and other healthcare organizations that elect to use the pathway, the operational challenge will be ensuring that the POA, dispensing records, receipt, storage, administration, security, and ultimate disposition of the medication are handled consistently with both federal and applicable state requirements.
Guidance or Rulemaking?
For many observers, the primary concern with DEA’s October 28, 2026 guidance will be not its policy objective, but whether DEA used the proper process to establish it.
The Administrative Procedure Act (APA) generally requires notice-and-comment rulemaking when an agency establishes substantive regulatory requirements, while interpretive rules and general policy statements are generally exempt from notice-and-comment procedure. The issue, therefore, is whether DEA is simply interpreting existing law or effectively creating a new regulatory pathway.
DEA acknowledges that pharmacies generally may not dispense controlled substances to practitioners because they are not the ultimate users and that Congress created specific exceptions to this rule. Nevertheless, the guidance establishes an additional pathway allowing a patient to designate an administering practitioner through a POA to accept delivery on the patient’s behalf.
The guidance goes beyond simply recognizing the use of a POA. It establishes operational expectations concerning dispensing, segregation, administration, verification and retention of the POA, and disposal of unused controlled substances. These requirements are likely to be viewed by at least some DEA registrants as having meaningful compliance consequences.
Although DEA describes the guidance as non-binding and states that it does not have the force and effect of law, those disclaimers do not necessarily resolve the APA question. The critical issue is what the guidance actually does, not simply how DEA labels it.
If the POA pathway is already authorized by the CSA and DEA regulations, DEA should be able to identify that authority. If, however, the guidance substantively expands when pharmacies may deliver controlled substances to practitioners, there is a strong argument that DEA should establish that pathway through notice-and-comment rulemaking.
Final Thought concerning 21 USC 829a
DEA may have identified a legitimate patient-safety and diversion concern. But a sound policy objective does not eliminate the requirements of the Administrative Procedure Act.
When an agency establishes a new framework governing how registrants handle controlled substances, notice-and-comment rulemaking provides transparency, public participation, and clearer regulatory expectations. Registrants should not be left to determine whether supposedly “non-binding” guidance will ultimately become the standard used during DEA inspections or enforcement actions.
Navigating new DEA guidance can create important compliance questions. Contact Brinks DEA Consulting to discuss how this policy may affect your pharmacy, practice, or healthcare organization and the steps you should consider in response.
Brinks DEA Consulting provides compliance consulting and regulatory guidance. This discussion is for informational purposes and does not constitute legal advice. 21 USC 829a